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Abstract
Background: Pelvic floor dysfunction (PFD) is a group of clinical conditions including stress urinary incontinence
(SUI) and pelvic organ prolapse (POP). The abnormality of collagen and elastin metabolism in pelvic connective
tissues is implicated in SUI and POP.
Methods: To reconstitute the connective tissues with normal distribution of collagen and elastin, we transduced
elastin to bone marrow-derived mesenchymal stem cells (BMSC). Elastin-expressing BMSCs were then differentiated
to fibroblasts using bFGF, which produced collagen and elastin. To achieve the sustained release of bFGF, we
formulated bFGF in poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NP).
Results: In an in vitro cell culture system of 7 days, when no additional bFGF was administrated, the initial PLGA-
loaded bFGF NP induced prolonged production of collagen and elastin from elastin-expressing BMSCs. In vivo,
co-injection of PLGA-loaded bFGF NP and elastin-expressing BMSCs into the PFD rats significantly improved the
outcome of urodynamic tests. Together, these results provided an efficient model of connective tissue engineering
using BMSC and injectable PLGA-loaded growth factors.
Conclusions: Our results provided the first instance of a multidisciplinary approach, combining both stem cell and
nanoparticle technologies, for the treatment of PFD.
Keywords: Pelvic floor dysfunction, Bone marrow-derived mesenchymal stem cells, Basic fibroblast growth factor,
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Background
Pelvic floor dysfunction (PFD) is the term for a group of
clinical conditions, including stress urinary incontinence
(SUI), pelvic organ prolapse (POP), overactive bladder
syndrome, and fecal incontinence. SUI and POP are
highly related to childbirth-associated pelvic floor injury
[1]. Studies have estimated that 50 % of parous women
have different degrees of SUI and POP. These disorders
are prevalent in adult women and their incidences in-
crease with age [2, 3]. Treatments for these conditions
are still conservative and symptom based. Women with
symptoms who have failed or declined conservative
management are candidates for surgery. Traditionally,
surgeries include anterior, posterior, or total repair of the
vagina, with concomitant hysterectomy, but the recur-
rence rate can be as high as 20–30 % [4, 5]. Eleven per-
cent of women over the age of 80 undergo surgery for
such conditions, with an additional 30 % requiring re-
peated surgery [2, 3]. Synthetic and biomaterial meshes
have been used recently to provide improved long-term
outcomes during surgical treatments; however, about
one-third of meshes cause scarring, erosion, and pain
[6]. Alternative methods are therefore needed to pro-
mote the repair and regeneration of damage tissues.
All symptoms of PFD can be associated with pelvic
floor defects. The pelvic floor support is provided by the
interaction between the muscles and connective tissues
within the pelvis, modulated by the neuro-pathway.
Weakness in any of components without compensation
will eventually increase the incidence of pelvic floor
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defects. Petros et al. [7] indicated that connective tissues,
rather than muscle damage, were probably the major
cause of SUI. Evidence suggests that abnormalities in
connective tissue structure or its repair mechanism may
be predispositions to prolapse [8]. Fibrous connective
tissue is defined as the extracellular matrix (ECM),
which mainly contains fibrous proteins including colla-
gen and elastin produced by fibroblasts in the ECM. Fi-
broblasts also secrete growth factors that modulate the
synthesis and breakdown of the fibers. Jackson et al. [9]
reported that deficient collagen metabolism in the con-
nective tissues may lead to PFD. Since then, the role of
fibroblasts that produce both collagen and elastin has
been studied widely. Both an increase [10–12] and a de-
crease [9, 13, 14] in the total content of collagen in con-
nective tissues by different methods have been reported
in PFD. Change in the ratio of subtypes of collagens and,
more importantly, deficient crosslinking of collagens are
involved in PFD [15–17]. Elastin, an insoluble polymer
of the monomeric soluble precursor tropoelastin, is the
main component of elastic fibers in the ECM in a variety
of connective tissues including the aorta and ligaments.
Elastin helps tissues to stretch and return to their ori-
ginal shape without energy input, which is extremely im-
portant in the regenerative system. Many studies have
shown that elastin metabolism is affected in PFD be-
cause of increased degradation, abnormal synthesis, and
interruption in elastin homeostasis [17–20].
Stem cells are able to participate in tissue repair due
to their multilineage differentiation ability, potentially
into various cell types of connective tissues, and there-
fore hold great promise for treating PFD. Bone marrow-
derived mesenchymal stem cells (BMSCs) are one of the
most well-characterized stem cell sources, have great dif-
ferentiation capabilities, and secrete bioactive factors
that benefit tissue repair [21]. In animal models of SUI,
periurethral injection of BMSCs restored the damaged
external urethral sphincter, and significantly alleviated
SUI symptoms [22, 23].
Basic fibroblast growth factor (bFGF) [24], a member
of the fibroblast growth factor family, is an important
growth factor for mesenchymal stem cell proliferation
[25], and is also required for the differentiation of
BMSCs into fibroblasts [24]. However, bFGF has a short
half-life, and therefore repeated injections are required
to maintain stable local concentration, resulting in a
high cost of relevant therapies. Better and more cost-
effective methods are therefore needed to maintain the
local concentration within the therapeutic duration.
Fibroblasts secrete collagen and elastin into connective
tissues, with collagen being the predominant compo-
nent. Elastic fibers play an important role in preventing
collagen forming or remodeling into dense tissues. Con-
tigen, a Food and Drug Administration (FDA)-approved
injectable collagen solution, was discontinued in 2011
because its injection caused the formation of dense scar
tissue comprising collagen without a significant amount
of elastin, which contributed to a recovery rate as low as
15 % in 3 years [26]. Li et al. [27] reported that transduc-
tion of elastin to BMSCs could enhance the production
of elastin, and transplantation of autologous BMSCs
overexpressing elastin preserved the connective tissues
with regional elasticity, preventing cardiac dilation and
improving cardiac functions. Therefore, the goal of our
current study is to reconstitute the connective tissues
with normal distribution of collagen and elastin that
would benefit the correction of pelvic support defects.
In the current study, we transduced primary cultured
rat BMSCs with a high-efficiency adenoviral vector over-
expressing elastin. To direct tissue repair and regener-
ation, the elastin-overexpressing BMSCs were induced
to differentiate into fibroblasts under the unique culture
condition, in which bFGF was encapsulated in poly(lac-
tide-coglycolide-co-caprolactone) polymer nanoparticles
(NPs)—the bFGF-loaded poly(lactic-co-glycolic acid)
(PLGA) system. This system allows sustained release of
bFGF into the culture. Injecting both the elastin-
expressing BMSCs and bFGF-loaded PLGA NPs into the
weakest position in the pelvis [28] of PFD rats has led to
sustained release of bFGF, local differentiation of BMSCs
to fibroblasts, as well as subsequent production of colla-
gen and elastin. We hereby demonstrate that transplant-
ation of elastin-expressing BMSCs improved conscious
cytometry (CMG) and leak point pressure (LPP) in a rat
PFD model. Our current study therefore provides a
novel and multidisciplinary approach, combining both
stem cell and NP techniques, to restore the pelvic floor
supportive function.
Methods
Primary rat BMSC isolation and culture
Six-month-old female Sprague Dawley rats were used in
the study. All animal studies were conducted in accord-
ance with the rules and regulations of the Institutional
Animal Care and Use Committee at Xinhua Hospital,
Shanghai Jiaotong University School of Medicine,
Shanghai, China. This study was approved by the ethics
committee at Xinhua Hospital. Femurs from the rats
were dislocated under anesthesia. Bone marrow cells
were flushed from the femurs using 10 ml syringes con-
taining 5–10 ml cold Iscove’s modified Dulbecco
medium (IMDM). The cell suspension was centrifuged
at 150 × g for 5 minutes, and the cell pellet was resus-
pended in IMDM. The cell suspension was layered onto
Percol separation solution (density 1.073 g/ml, Sigma-
Aldrich, St. Louis, MO, USA) and centrifuged at 400 × g
for 30 minutes at 26 °C. The resulting cotton-like cells
at the interface were collected and rinsed once. Cells
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were then cultured with IMDM supplemented with 20 %
fetal bovine serum and 1 % streptomycin/penicillin
(Sigma-Aldrich, St. Louis, MO, USA). The medium was
changed after 24 hours and cells were maintained in the
same medium until reaching approximately 80 % conflu-
ence. Cells were then trypsinized, replated, and cultured
until the second passage. The yields of plastic-adherent,
fibroblast-like cells from these two passages were ob-
tained and considered the mesenchymal stem cells.
These cells are harvested for characterization and used
for the elastin virus infection.
Transduction of BMSCs with elastin-expressing adenovirus
vector
Transduction of BMSCs with elastin-expressing adeno-
virus vector was performed according to previously de-
scribed methods [27]. The coding region of rat elastin
was amplified by PCR. The PCR product was then
cloned into a modified adenovirus (Ad) vector under
control of the cytomegalovirus (CMV) promoter green
fluorescent protein (GFP) (Ad-CMV-GFP). The final
construct was referred to as Ad-CMV-GFP-elastin and
confirmed by DNA sequencing. To generate the virus
particle, AD-293 cells were transfected with Ad-CMV-
GFP-elastin or empty vector Ad-CMV-GFP. Twenty-
four hours after transfection, the medium was changed
and transfected cells were cultured for 10–14 days. The
supernatant (primary virus stock) was then harvested.
The plaque forming units of the virus stock were mea-
sured by infecting AD-293 cells and counting the num-
ber of GFP-positive cells. The virus stock was also tested
by PCR to confirm the presence of the elastin genes. To
infect the BMSCs, the primary virus stock of Ad-CMV-
GFP-elastin or Ad-CMV-GFP was added to BMSCs and,
after incubation for 24 hours, medium containing the
virus was replaced with complete culture medium and
the cells were incubated for an additional 24 hours. The
efficiency of infection was evaluated by the percentage
of GFP-positive cells. Five days after infection, cells were
harvested for evaluation of elastin expression by western
blotting and PCR. No alteration of BMSC surface CD
marker was observed by flow cytometry.
Formulation of bFGF-loaded poly(lactide-coglycolide-co-
caprolactone) polymer NPs
Formulation of PLGA-NPs was performed according to
previously described methods [29, 30]. A double emul-
sion–solvent evaporation method (water–oil–water) was
employed for the formation of bFGF-encapsulated NPs.
Briefly, 20 g of PLGA was dissolved in an appropriate
amount of dichloromethane. The solution was then
injected into the inner aqueous phase (W1, 100 μl of
phosphate-buffer saline (PBS)) containing bFGF. The
bFGF-W1 was emulsified with the polymer solution and
the formation of small polymer droplets was facilitated
by a high-speed IKA Ultra Turrax homogenizer (IKA,
Guangzhou, China) operating at 225 × g for 2 minutes.
The resulting emulsion (W1/O) was added to a larger
aqueous phase (W2). A multiple emulsion (W1/O/W2)
was achieved by homogenization with a high-speed
homogenizer at the selected speed and time. After the
complete evaporation of organic solvent with an evapor-
ator, the copolymer was precipitated and formed solid NPs,
which were collected by centrifugation. NPs were frozen in
liquid nitrogen prior to lyophilization for freeze-drying.
Analysis of BMSC surface markers by flow cytometry
The expressions of cell surface markers on BMSCs were
evaluated by flow cytometry. BMSCs were harvested and
stained with fluorescein isothiocyanate-conjugated mouse
anti-rat CD44, CD73, CD90, and CD45, and affinity-
purified mouse IgG1 as isotype control. Fluorescence-
activated cell sorting was performed with FACSDiva (Canto,
BD Bioscience, San Jose, CA, USA) and data were analyzed
with FlowJo software (Tree Star, Ashland, OR, USA).
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium
bromide assay
BMSCs were seeded at 10,000 cells per well in six-well
plates and were incubated in 5 % carbon dioxide at 37 °C.
At assay-specific time points, culture medium was re-
placed and wells were washed twice with PBS. In the
growth curve experiment, 10 μl of 3-(4,5-Dimethyl-2-thia-
zolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT,
0.5 mg/ml) was added and the culture was incubated for
4 hours. The culture medium was discarded and was re-
placed with 100 μl isopropanol/HCl. Absorbance at
570 nm was measured using a microplate reader. Relative
viability was calculated using the following formula:
Relative viability ¼
experimental absorbance – background absorbanceð Þ=
untreated controls’ absorbance – background absorbanceð Þ
 100 %:
Reverse transcription-PCR
Total RNA was extracted from cells using the RNeasy
Plus Mini Kit (Qiagen, Gaithersburg, MD, USA). The
cDNA was synthesized with the QuantiTect Reverse
Transcription Kit (Qiagen) according to the manufac-
turer’s instructions. Expression levels were normalized to
GAPDH. PCR was performed using the following
primers: elastin, forward 5′-CTT CCT GGT GGA GTT
CCC GGT GGA-3′, reverse 5′-CCG ATG CCA CCA
ATA CCA CCG ACA-3′; collagen, forward 5′-GGA
GAG TAC TGG ATC GAC CCT-3′, reverse 5′-CTG
ACC TGT CTC CAT GTT GCA-3′; and GAPDH,
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forward 5′-ACC ACA GTC CAT GCC ATC AC-3′, re-
verse 5′-TCC ACC ACC CTG TTG CTG TA-3′.
Western blotting
Cell or tissue samples were extracted with RIPA buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM ethyl-
enediamine tetraacetic acid, 1 % Triton X-100, 1 %
sodium deoxycholate, 0.1 % sodium dodecyl sulfate, sup-
plemented with protease inhibitors), and the total protein
content was measured using the bicinchoninic acid protein
assay kit (Thermo Scientific, Waltham, MA, USA). Pro-
teins were resolved using denaturing SDS-PAGE followed
by transferring onto nitrocellulose membrane. Primary
antibodies against elastin (sc-17581), collagen (sc-8784),
and actin (sc-8432) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Actin was used as the
loading control. The immunoblot signal was detected using
SuperSignal West Pico substrate (Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assay
Measurement of rat elastin and collagen was performed
by enzyme-linked immunosorbent assay (ELISA) kits
(Abbexa, Cambridge, UK) according to the manufac-
turer’s instructions. Briefly, collagen and elastin in sam-
ples was captured by the specific primary antibody and
detected by the biotin-labeled secondary antibody. The
assays were developed by avidin-peroxidase and its sub-
strate, and plates were read at 450 nm using a micro-
plate reader.
Rat PFD model
The rat vaginal distention translational model with
modification was set up in the study [31]. Briefly, an
18 F catheter was inserted into the rat vagina and then
fixed with a single 3–0 silk suture. The Foley balloon
was inflated with water (2.5–3.0 ml) and connected to a
pressure transducer (about 0.15 kg) to create pressure
on the pelvic floor support tissue. After 4 hours, the
catheter was deflated and removed along with the pres-
sure transducer from the vagina. Fourteen days after va-
ginal distention the LPP and CMG were assayed to
ensure the establishment of the PFD model, and later for
the evaluation of treatment outcome.
Conscious cytometry
Two days before CMG, a bladder catheter (PE-50 tubing
with a flared tip) was inserted into the PFD rat. The
catheter was connected to a syringe pump (KD Scien-
tific, New Hope, PA, USA) and a pressure transducer
(Grass Instruments, West Warwick, RI, USA). Each
bladder was filled with saline via the catheter at 5 ml/
hour. A voiding contraction was defined as an increase
of bladder pressure that resulted in urine loss as
detected by a force transducer (Grass Instruments) that
was calibrated to measure volume. Three fills and voids
were recorded for each rat. Mean bladder baseline pres-
sure, mean voided volume, mean peak voiding pressure,
and mean increase in bladder pressure for voiding (peak
voiding pressure minus bladder baseline pressure) were
calculated for each animal with a chart recorder.
LPP test
Two days before the LPP test, a bladder catheter (PE-
50 tubing with a flared tip) was inserted into the PFD
rat and connected via a stopcock to the pressure trans-
ducer and flow pump. Under anesthesia with urethane
(1.2 g/kg body wt intraperitoneally), the bladder was
palpated to empty and filled with saline at 5 ml/hour
via the flow pump. When 0.3 ml was attained (approxi-
mately half the capacity of a 200 g rat), gentle pressure
was applied with one finger to the rat’s abdomen to in-
crease bladder pressure while bladder pressure was re-
corded and digitized. Pressure was slowly increased
until the rat leaked saline through the urethra. At the
first indication of leakage at the urethral meatus, the
externally applied abdominal pressure was removed
rapidly. Peak pressure at leakage in the absence of a de-
trusor contraction was recorded. The LPP was calcu-
lated by subtracting the bladder baseline pressure from
the peak bladder pressure. The bladder was drained
and refilled, and the study was repeated three times for
each rat. Mean bladder baseline pressure and mean
LPP were calculated for each rat.
Statistical analysis
Statistical analyses were performed using SPSS software
(SPSS Inc., Chicago, IL, USA). Results are shown as the
mean ± standard deviation (SD). A two-group compari-
son was performed using the unpaired Student t test,
and P <0.05 was considered statistically significant.
Results
Characterization of elastin-expressing BMSCs
There are two kinds of stem cells in the bone marrow:
mesenchymal and hematopoietic stem cells. To initiate
the characterization of BMSCs, expression of the cell sur-
face markers specific for mesenchymal and hematopoietic
stem cells was analyzed by flow cytometry. All analyzed
cells were positive for mesenchymal cell markers CD44,
CD73, and CD90, but negative for hematopoietic cell
marker CD45 (Fig. 1), confirming the identity of isolated
BMSCs.
Next to confirm expression of the elastin gene, BMSCs
infected with Ad-CMV-elastin-GFP were harvested
24 hours after infection. PCR and western blotting were
performed to check the mRNA and protein expressions
of elastin. Compared with BMSCs infected with empty
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vector Ad-CMV-GFP, BMSCs infected with Ad-CMV-
elastin-GFP expressed significantly elevated elastin, both
at mRNA and protein levels (Fig. 2).
bFGF-loaded PLGA NPs promoted the proliferation of
elastin-expressing BMSCs in vitro
The NP formulation provided a sustained bFGF release,
which could serve as a reliable source of bFGF to pro-
mote the proliferation of BMSCs. We first measured the
bFGF release curve in vitro. bFGF-loaded PLGA NPs
(equivalent concentration 20 ng/ml) were incubated in
medium for 7 days. The medium was harvested every
day to assay for the release of bFGF using ELISA. As
shown in Fig. 3a, approximately 70 % of bFGF was re-
leased from the NPs within the first 5 days in a consist-
ent and sustained pace. The rest of the bFGF continued
to be released until the end of the experiment at day 7.
Next, the bioactivity of the bFGF released from the
PLGA NPs was evaluated via the induction capacity of
BMSC proliferation. Elastin-expressing BMSCs were
cocultured for 7 days with bFGF-loaded PLGA NPs at
equivalent concentration 20 ng/ml (Fig. 3b, bFGF-
PLGA), free bFGF at 20 ng/ml (Fig. 3b, bFGF), and
empty PGLA as negative control (Fig. 3b, PLGA). No
additional bFGF was supplemented in the culture (see
Discussion). Cells were harvested daily for 7 consecutive
days to measure proliferation using the MTT assay. In
the empty PLGA NP control group, in the absence of
bFGF, cells did not proliferate. Cells incubated with free
bFGF proliferated in the first 4 days and the culture
nearly doubled at day 4. However, cells stopped prolifer-
ating in the absence of replenishing bFGF, reaching the
plateau after day 5. In contrast, cells incubated with
bFGF-loaded PLGA proliferated as fast as the free bFGF
group in the first 4 days. More importantly, with the
sustained supply of bFGF released from the bFGF-
loaded PLGA NPs, cells proliferated continuously with
prolonged incubation time even after day 5. Taken to-
gether, the bFGF-loaded PLGA NP system proved to be
an ideal sustained release system to be used for further
experiments in our current study.
bFGF-loaded PLGA promoted the expression and
secretion of elastin and collagen in differentiated BMSCs
in vitro
The induction capacity of bFGF on the expression and
secretion of elastin and collagen was investigated in dif-
ferentiated BMSCs. Four different experimental groups
were established: BMSC + bFGF, naked BMSCs cultured
with free bFGF at 20 ng/ml; BMSC + bFGF-PLGA,
naked BMSCs cultured with bFGF-loaded PLGA NPs at
an equivalent concentration of 20 ng/ml; elastin-BMSC
+ bFGF, elastin-expressing BMSCs cultured with free
bFGF at 20 ng/ml; and elastin-BMSC + bFGF-PLGA,
Fig. 1 Flow cytometry identified rat BMSC-positive markers CD44, CD73,
and CD90, but not negative marker CD45, on the surface of the cells
Fig. 2 Effect of elastin transduction in BMSCs. Levels of mRNA a and
protein b of elastin in BMSCs were examined 24 hours after transduction.
Values are mean ± SD. *P <0.05 vs control
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elastin-expressing BMSCs cultured with bFGF-loaded
PLGA NPs at an equivalent concentration of 20 ng/ml.
Cells in all four groups were cultured in proliferation
medium for 7 days and then changed to differentiation
medium for a further 7 days. At the end of the experi-
ment, cells from each group were harvested for evalu-
ation of intracellular elastin and collagen expression
using reverse transcription (RT)-PCR and western blot-
ting, and supernatants of cell culture were also collected
to measure the secretion of elastin and collagen into cul-
ture media using ELISA. In both RT-PCR and western
blotting analysis, significantly increased expressions of
elastin and collagen were observed in both groups of
elastin-expressing BMSCs, compared with those from
BMSCs not expressing elastin, regardless of incubation
with either free bFGF or bFGF-loaded PLGA (Fig. 4a, b).
In addition, administration of bFGF-loaded PLGA NPs
to the elastin-expressing BMSCs further upregulated the
expression of elastin and collagen, compared with the
same cells incubated with free bFGF. Consistently, co-
culture of elastin-expressing BMSCs with bFGF-loaded
PLGA exhibited a higher extent of stimulation on the se-
cretion of elastin and collagen, compared with the same
cells cocultured with free bFGF (Fig. 4c). These results
indicated that overexpressing elastin in the BMSCs not
only upregulated the expression of elastin itself, but also
stimulated the intracellular production of collagen as
well as extracellular secretion of both elastin and
collagen.
Transplantation of elastin-expressing BMSCs improved
urodynamic testing in the rat PFD model
We next tested whether the elastin-expressing BMSCs
could alleviate PFD symptoms in vivo, by establishing a
rat PFD model. Six-month-old female Sprague Dawley
rats were randomly and evenly divided into six experi-
mental groups (n = 8 each): Control rats, normal rats
without any intervention served as healthy controls
throughout the duration of the experiment; PFD rats, sa-
line was injected into the weakest position of the pelvis
[28] 14 days after vaginal distention was performed on the
rats to induce PFD symptoms (see Methods); BMSC+
bFGF rats, naked BMSCs and free bFGF were coinjected
into PFD rats 14 days after operation; BMSC + PLGA-
bFGF rats, naked BMSCs and bFGF-loaded PLGA were
coinjected into PFD rats 14 days after operation;
elastin-BMSC + bFGF rats, elastin-expressing BMSCs
and free bFGF were coinjected into PFD rats 14 days
after operation; and elastin-BMSC + PLGA-bFGF rats,
elastin-expressing BMSCs and bFGF-loaded PLGA
were coinjected into PFD rats 14 days after operation.
Seven days after injection, the two urodynamic tests
of CMG and LPP were performed in all of these ex-
perimental groups of rats.
In the CMG test, similar levels of bladder baseline
pressure were observed in all experimental groups of
rats (Fig. 5a). As expected, the void volume and bladder
void pressure were significantly decreased in the PFD
rats compared with the Control rats (Fig. 5b, c, first and
second columns), suggesting the successful establish-
ment of a rat PFD model. Coinjection of naked BMSCs
along with either free bFGF or bFGF-loaded PLGA did
not reverse the decreased void volume or bladder void
pressure (Fig. 5b, c, third and fourth columns). In con-
trast, both the decreased void volume and bladder void
pressure were reversed in rats receiving injections of
elastin-expressing BMSCs (Fig. 5b, c, fifth and sixth col-
umns). More importantly, aided by the sustained release
of bFGF from PLGA NPs, the void volume and bladder
void pressure of elastin-BMSC + bFGF-PLGA rats were
almost completely restored to the same level as the Con-
trol rats (Fig. 5b, c, sixth column).
In LPP testing, the peak bladder pressure and LPP
were also significantly decreased in PFD rats compared
with the Control rats (Fig. 6a, b, first and second col-
umns), which further demonstrated the successful
Fig. 3 bFGF-PLGA promotes the proliferation of BMSCs. a In vitro cumulative release profile of bFGF-loaded PLGA. b Elastin-transfected BMSCs
were cultured in the presence of either empty PLGA, free bFGF without PLGA (bFGF), or bFGF-loaded PLGA (bFGF-PLGA), and cell proliferation
was measured by MTT assay. bFGF basic fibroblast growth factor, PLGA poly(lactic-co-glycolic acid)
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establishment of a rat PFD model in our current study.
Expectedly, coinjection of naked BMSCs along with ei-
ther free bFGF or bFGF-loaded PLGA had minimal im-
pact on peak bladder pressure and LPP (Fig. 6a, b, third
and fourth columns), compared with PFD rats. Injection
with elastin-expressing BMSCs reversed the decreased
void volume and bladder void pressure (Fig. 6a, b, fifth
and sixth columns). Furthermore, when coinjected with
bFGF-loaded PLGA, elastin-expressing BMSCs rescued
the decreased peak bladder pressure and LPP to a level
indistinguishable from those of Control rats (Fig. 6a, b,
sixth column).
In summary, gene modification of BMSCs without
elastin had minimal effect on the outcomes of urody-
namic tests in PFD rats, regardless of the source of
bFGF. Together with the sustained release of bFGF from
PLGA NPs, however, elastin-expressing BMSCs signifi-
cantly improved the outcome of urodynamic tests to
levels similar to those of healthy rats.
Discussion
Weakening of pelvic connective tissues is considered a
contributing factor in PFD. Elastin is a critical compo-
nent of vaginal and pelvic floor connective tissues. In-
creasing numbers of studies have begun to focus on the
role of elastin in the pathophysiological development of
PFD, especially in SUI and POP, both of which are asso-
ciated with childbirth injuries. During delivery, disten-
tion of the vagina results in the degradation of elastin
fibers. Destructed elastin fibers are improperly orga-
nized, leading to malfunction which eventually causes
tissue stiffness. Studies in a mouse model of defective
elastin have suggested that elastic fiber synthesis is a
critical process of childbirth recovery, and impaired elas-
tin synthesis leads to prolapse [32]. The prevalence of
PFD is high in women and current treatment options
are suboptimal.
Given that altered elastin metabolism and connective
tissue abnormality represent the major pathophysio-
logical development of PFD, our study focused on an
elastin gene-modified, stem-cell based, and NP-mediated
multidisciplinary therapy for the repair and regeneration
of pelvic floor tissues in PFD. To alter the matrix com-
position and change the properties of the damaged stiff
tissue, we introduced the elastin gene into BMSCs which
were then transplanted into the vaginal distension-
induced damaged tissue in adult rats. We demonstrated
that bFGF-loaded PLGA NPs could markedly stimulate
the secretion of collagen and elastin, following differenti-
ation of elastin-expressing BMSCs to fibroblasts. Trans-
plantation of elastin-expressing BMSCs in vivo yielded
favorable therapeutic effects on PFD rats, where bFGF-
loaded PLGA provided sustained release of bFGF and
further enhanced the beneficial effects of elastin-
expressing BMSCs.
Mesenchymal stem cells have already exhibited great
potential in soft tissue reconstruction [33, 34]. In a re-
cent in vivo study on PFD [35], transplantation of
BMSCs resulted in new tissue growth and collagen de-
posit in a wound-healing model. In the context of PFD,
to functionally restore pelvic floor support, an appropri-
ate amount of elastic fibers in the connective tissue is
extremely important. Simple deposition of collagen
would cause formation of dense connective tissues and
Fig. 4 bFGF-PLGA promotes the expression and secretion of elastin
and collagen in differentiated BMSCs. BMSCs with or without elastin
transduction were differentiated in the presence of either bFGF
or bFGF-PLGA for 7 days. Levels of mRNA a and protein b, and
concentration in medium c of elastin and collagen were examined by
RT-PCR, western blot, and ELISA assays. Values are mean ± SD. *P <0.05
vs BMSC+ bFGF and BMSC+ bFGF-PLGA. #P <0.05 vs elastin-BMSC +
bFGF. bFGF basic fibroblast growth factor, BMSC bone marrow-derived
mesenchymal stem cell, PLGA poly(lactic-co-glycolic acid)
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eventually scar tissues. The potential solution is elastin
gene-engineered cell therapy [27], where overexpressing
elastin in BMSCs has led to restoration of elasticity in
the dilated cardiac tissue and recovery of cardiac func-
tion. Consistent with previous study [27], elastin-
expressing BMSCs produced sufficient elastin and colla-
gen in our rat PFD model to restore the function of tis-
sues damaged by virginal distention.
Fibroblasts in the vaginal wall were sensitive to the
mechanical stretch during delivery [36]. When cultured
with mechanical stretching, fibroblasts isolated from the
vaginal wall in women suffering from POP grew perpen-
dicular to the direction of the force, and exhibited de-
creased cell projection area and cell circularity, and
increased cell length/width ratio, suggesting that POP fi-
broblasts have greater sensitivity and less tolerance for
mechanical stretching [37]. Repeated mechanical
stretching eventually leads to a degradation response of
fibroblasts. Theoretically, recovery in the quantity and
function of fibroblasts should be beneficial for tissue re-
pair, and therefore replacement of the damaged fibro-
blasts at the injury site using mesenchymal stem cell
therapy could be beneficial. In our study, elastin-
expressing BMSCs supplemented with bFGF produced
sufficient elastin and collagen in vitro, and exhibited sig-
nificant beneficial effects on PFD rats in vivo, although
the exact mechanism underlying the improved clinical
outcome was not well defined because the development
of mesenchymal stem cell transplantation therapy is still
in the early stage.
Although the fate of transplanted BMSCs after injec-
tion is unclear, limited long-term engraftment is com-
monly seen [38]. No prelabeled stem cells were found
up to 14 days in the injection site, even though the bio-
activity of the stem cells can last much longer, with a
possible explanation being that the stem cells undergo
proliferation and differentiation quickly. Nevertheless,
controlling the fate and the phenotype of engrafted
BMSCs in tissues remains a big challenge. Unlike in
vitro cell culture, where growth factors such as bFGF
used in our current study can be resupplied easily and
readily, growth factors distribute quickly inside the tis-
sue in the bioenvironmental milieu and degrade rapidly.
Replenishing growth factors in vivo is challenging, even
though repeated high-dose injection could be an alter-
native albeit expensive way. Besides, burst doses,
Fig. 5 bFGF-PLGA and elastin transfection improve CMG in PFD rats after BMSC transplantation. The rat PFD model was established and housed
for 14 days, after which the rats were transplanted with BMSCs and housed for a further 7 days. CMG including a bladder baseline pressure, b void
volume, and c bladder void pressure was then performed on all rats (n = 8) in each experimental groups. Values are mean ± SD. *P <0.05 vs Control.
#P <0.05 vs PFD. $P <0.05 vs Control and elastin-BMSC+ bFGF. bFGF basic fibroblast growth factor, BMSC bone marrow-derived mesenchymal stem
cell, PFD pelvic floor dysfunction, PLGA poly(lactic-co-glycolic acid)
Fig. 6 bFGF-PLGA and elastin transfection improve LPP in PFD rats after BMSC transplantation. The PFD rat model was established and housed
for 14 days, after which the rats were transplanted with BMSCs and housed for a further 7 days. a Peak bladder pressure and b LPP were then
performed on all rats (n = 8) in each experimental group. Values are mean ± SD. *P <0.05 vs Control. #P <0.05 vs PFD. $P <0.05 vs Control and
elastin-BMSC + bFGF. bFGF basic fibroblast growth factor, BMSC bone marrow-derived mesenchymal stem cell, PFD pelvic floor dysfunction, PLGA
poly(lactic-co-glycolic acid)
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inconsistent local concentration, high cost, and
injection-associated complications are obvious disad-
vantages. Moreover, the lack of growth factors in trans-
planted stem cells leads to variability in cell function
and ultimately poor therapeutic outcomes.
PLGA provides a platform to control the local
pharmacokinetics of growth factors, and in turn the pro-
liferation and differentiation of transplanted stem cells.
As an FDA-approved drug delivery device, PLGA NPs
can be easily processed and fabricated in various forms
and sizes, and have many attractive properties, such as
biocompatibility and biodegradability. In our current
study, PLGA was used to control the sustained release
of bFGF. Comparing the elastin-expressing BMSCs
cocultured with either free bFGF or bFGF-loaded PLGA,
the latter experimental group exhibited enhanced ex-
pression and secretion of both collagen and elastin in
vitro. In the rat PFD model, bFGF-loaded PLGA along
with elastin-expressing BMSCs significantly alleviated
the PFD symptoms. We speculated that delivery of the
growth factor in a controlled and sustained manner
could maintain the therapeutic effects of transplanted
BMSCs over time and effectively direct the differenti-
ation of stem cells, where their ability to secret elastin
and collagen was subsequently improved. In this context,
our current report may provide a proof-of-principle
study that the combinational stem cell and NP therapy
would be useful and very interesting to apply in future
PFD-related investigations, particularly the correlation
between the prolapse stage and proliferation after 7 days,
as well as the mechanical properties of tissues in the
PFD animal model.
Conclusion
We have demonstrated in the first instance that trans-
plantation of elastin-expressing BMSCs into PFD rats
could significantly alleviate the symptoms of PFD. This
beneficial effect could be further enhanced by sustained
released of bFGF from PLGA NPs. By taking a multidis-
ciplinary approach combining genetic modification, stem
cell therapy, and NP techniques, our current study pre-
sented an efficient and promising method using genetic-
ally modified BMSCs to promote the reconstitution of
connective tissue defects and to treat PFD.
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